Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.

Trial Profile

Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Eribulin (Primary) ; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms ERIGE
  • Most Recent Events

    • 06 Jun 2017 Results (n=83), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 12 Dec 2015 Trial design presented at the 38th Annual San Antonio Breast Cancer Symposium
    • 06 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top